摘要
目的:评价武汉地区医院调脂药的利用状况及发展趋势。方法:对武汉地区32家医院2009-2011年调脂药品种、销售金额、用药频度(DDDs)、日均费用等进行统计、分析。结果:3年中,调脂药的品种数、销售金额及DDDs均逐年增加;他汀类、中成药类及贝特类始终占据调脂药市场的主导地位,三者的DDDs之和占总DDDs的比例超过94.40%;他汀类药的DDDs显著上升,且该地区医院有集中使用该类药的倾向;DDDs排名列前10位的药品中,阿托伐他汀以绝对优势占据调脂药市场的首位,瑞舒伐他汀年均增幅最快。结论:他汀类调脂药将长期占有较大的市场份额;调脂药市场将进一步扩大,开发高效、低毒的新型调脂药有广阔的市场前景。
OBJECTIVE： To evaluate the situation and developing trend of the utilization of lipid regulating agents in hospitals of Wuhan area. METHODS： The utilization of lipid regulating agents in hospitals during the period of 2009--2011 were analyzed statistically in respect of varieties, consumption sum, DDDs, DDC, etc. RESULTS： Over 3 consecutive years, the varieties, con- sumption sum and DDDs of lipid regulating agents increased year by year; statins, Chinese patent medicines and fibrates always oc- cupied the top position of lipid regulating agents market, whose sum of DDDs occupied more than 94.40 % of total DDDs; DDDs of statins increased significantly, and there was an inclination to concentrate use statins in Wuhan area; among top 10 drugs in the list of DDDs, atorvastat occupied the first position of lipid regulating agents market with an absolute advantage, and the annual growth rate of rosuvastatin was the highest. CONCLUSIONS： Statins lipid regulating agents will occupy larger market share for a long time; the market of lipid regulating agents will further expand in China. New lipid regulating agents, that have high perfor- mance and low adverse reactions, should have a greater market potential.
出处
《中国药房》
CAS
CSCD
2013年第14期1258-1261,共4页
China Pharmacy
关键词
调脂药
用药频度
销售金额
日均费用
用药分析
Lipid regulating agents
DDDs
Consumption sum
DDC
Analysis of drug use
